Candel Therapeutics (CADL) — Fundamentals Overview

By Blake Campbell • Friday, May 19 12:19 • Permanent Link

Candel Therapeutics sank -7.6% today, compared to the S&P 500's day change of -0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

Candel Therapeutics has moved -51.3% over the last year, and the S&P 500 logged a change of 7.6%
CADL has an average analyst rating of buy and is -84.41% away from its mean target price of $10.2 per share
Its trailing earnings per share (EPS) is $-0.66
Candel Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -2.4 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-0.97 and its forward P/E ratio is -1.6
The company has a Price to Book (P/B) ratio of 0.96 in contrast to the S&P 500's average ratio of 2.95
Candel Therapeutics is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.